Shuttle Pharmaceuticals Holdings (SHPH) Non-Current Assets (2021 - 2026)
Shuttle Pharmaceuticals Holdings (SHPH) recorded quarterly Non-Current Assets of $9.3 million in Q1 2026, down 6.28% quarter-over-quarter from $10.0 million in Q4 2025, and up 2564.36% on a YoY basis from $350793.0 in Q1 2025.
Shuttle Pharmaceuticals Holdings (SHPH) Non-Current Assets (2021 - 2026) Analysis & Trends
Shuttle Pharmaceuticals Holdings' Non-Current Assets history runs 6 years deep, the most recent figure standing at $9.3 million for Q1 2026.
- In Q1 2026, Non-Current Assets rose 2564.36% year-over-year to $9.3 million; the TTM figure through Mar 2026 stood at $19.9 million (up 1448.07% YoY), while the FY2025 annual figure was $10.0 million, up 3276.43% from the prior year.
- Non-Current Assets was $9.3 million for Q1 2026 at Shuttle Pharmaceuticals Holdings, down from $10.0 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $10.0 million in Q4 2025 to a low of $64616.0 in Q1 2023.
- Historically, Non-Current Assets has averaged $1.5 million across 5 years, with a median of $327665.0 in 2024.
- The sharpest annual moves came in 2022 and 2025: Non-Current Assets slumped 47.06% in 2022, then soared 3276.43% in 2025.
- A 5-year view of Non-Current Assets shows it stood at $75194.0 in 2022, then soared by 377.07% to $358731.0 in 2023, then decreased by 17.66% to $295373.0 in 2024, then jumped by 3276.43% to $10.0 million in 2025, then decreased by 6.28% to $9.3 million in 2026.
- The last three Non-Current Assets figures came in at $9.3 million (Q1 2026), $10.0 million (Q4 2025), and $277014.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 26.33 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 8.68 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 3.84 Bn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 2.47 Bn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 9.64 Bn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 2.90 Bn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 1.22 Bn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 1.40 Bn |
| 10 | Shuttle Pharmaceuticals Holdings | 2.17 Mn | 1.11 Mn | - | 9.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.35 Mn |
| Dec 31, 2025 | 9.97 Mn |
| Sep 30, 2025 | 277,014.00 |
| Jun 30, 2025 | 312,512.00 |
| Mar 31, 2025 | 350,793.00 |
| Dec 31, 2024 | 295,373.00 |
| Sep 30, 2024 | 312,217.00 |
| Jun 30, 2024 | 327,665.00 |
| Mar 31, 2024 | 342,902.00 |
| Dec 31, 2023 | 358,731.00 |
| Sep 30, 2023 | 380,210.00 |
| Jun 30, 2023 | 393,759.00 |
| Mar 31, 2023 | 64,616.00 |
| Dec 31, 2022 | 75,194.00 |
| Sep 30, 2022 | 92,530.00 |
| Dec 31, 2021 | 142,026.00 |